Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

NARecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

April 1, 2026

Study Completion Date

June 1, 2028

Conditions
Focal Segmental Glomerulosclerosis
Interventions
DEVICE

LIPOSORBER® LA-15

"LIPOSORBER® LA-15 is a blood purification therapy; selectively removes apoprotein B-containing lipoproteins such as LDL from circulating blood and rapidly reduces the plasma cholesterol level. It was originally developed for prevention of coronary atherosclerosis progression in patients with serious hyperlipidemia such as familial hypercholesterolemia.~In the late 1980's, LDL-A was used to improve dyslipidemia in Nephrotic Syndrome, initially to prevent organ damage. LDL-A was found to improve both the dyslipidemic condition and clinical symptoms (proteinuria and hypoproteinemia)."

Trial Locations (10)

10065

RECRUITING

Weill Cornell Medicine / NewYork-Presbyterian, New York

19803

RECRUITING

Nemours/Alfred I DuPont Hospital for Children, Wilmington

23298

RECRUITING

Children's Hospital of Richmond at VCU, Richmond

27599

RECRUITING

University of North Carolina, Chapel Hill

29425

RECRUITING

Medical University of South Carolina Children's Hospital, Charleston

RECRUITING

Medical University of South Carolina, Charleston

44308

RECRUITING

Akron Children's Hospital, Akron

49503

RECRUITING

Helen DeVos Children's Hospital, Grand Rapids

92354

RECRUITING

Loma Linda University Children's Hospital, Loma Linda

RECRUITING

Loma Linda University Hospital, Loma Linda

All Listed Sponsors
lead

Kaneka Medical America LLC

INDUSTRY